SiliconBeat

Louis Lange, the chief executive of CV Therapeutics, agreed in effect to sell his entire stake in the company to Gilead Sciences as an “inducement” to that company to enter into an agreement to buy CV Therapeutics for $20 a share, according to a filing today with the SEC. Lange owns about Read the rest of this entry »

CV Therapeutics, the Palo Alto biopharmaceutical company fending off unsolicited overtures from Japan’s second largest drug company, reported today that its new oral compound CVT-3619, designed to treat cardiometabolic diseases, was “well tolerated “with no serious adverse events and was associated with a reduction of free fatty acids.”

The Phase 1, single-blind, placebo-controlled, single-ascending-dose study involved  55 healthy and 23 obese volunteers. “No clinically meaningful changes in Read the rest of this entry »

Astellas Pharma is appealing directly to the stockholder of CV Therapeutics, offering to give them $16 a share, an offer it has unsuccessfully made twice before to CV’s board, most recently a week ago.

“While we continue to prefer to reach a negotiated agreement Read the rest of this entry »

CV Therapeutics, the Palo Alto maker of the chest-pain treatment drug, Ranexa, said Friday the company’s board turned down an offer to buy it for $16 a share from Japan’s second-largest drug maker, Astellas Pharma.

We posted last month about the first offer Read the rest of this entry »

The board of directors at CV Therapeutics decided to extend by a year the shareholders rights plan they have in place to fend off hostile takeovers. The plan, otherwise known as a poison pill, was set to expire Read the rest of this entry »

CV Therapeutics said Thursday that European officials gave it the OK to market ranolazine, its treatment for patients suffering from angina, in all 27 states of the European Union. The move comes months after the European Medicines Agency gave a positive opinion Read the rest of this entry »